Resonance Health Ltd stock analysis
Want to see AU:RHT full AI Analyst Report?
The multi-year revenue scale-up indicates broader commercial adoption of the company’s imaging software and related services. Continued expansion of the revenue base can support operating leverage, strengthen the platform’s market presence, and provide a larger foundation for future cash generation.
A return to positive EBIT and net income improves the company’s ability to fund operations internally and reduces reliance on external capital. If profitability is sustained, it can support reinvestment in imaging technology, commercialisation, and customer expansion over coming periods.
Positive operating and free cash flow, with free cash flow broadly aligned with earnings, suggests that the latest profit recovery is converting into usable cash. This strengthens funding capacity for ongoing operations and growth while improving resilience compared with the prior year.
The sharp movement between profit and loss shows that reported earnings have not yet demonstrated consistent stability. Such volatility makes future profitability harder to rely on, can complicate investment planning, and may constrain confidence in the durability of the latest recovery.
The history of negative operating and free cash flow indicates that cash conversion has varied materially across the cycle. Even with a strong 2026 rebound, renewed weakness could reduce internally funded investment capacity and make the business more dependent on financing.
Although leverage is moderate and improved versus 2025, debt remains higher than in the earlier period when borrowing was very low. This reduces financial flexibility if profitability weakens again, because interest and repayment obligations could compete with growth investment.
Resonance Health Ltd ( ($AU:RHT) ) has issued an announcement. Resonance Health, an Australian healthcare company providing clinical-trial site and research services through its TrialsWest network, has appointed an experienced
Resonance Health Ltd ( ($AU:RHT) ) has issued an update. Resonance Health has reported preliminary extended proof-of-concept results for its FibrosisAssessment MRI-based liver fibrosis software, showing diagnostic accuracy comparable to
Resonance Health Ltd ( ($AU:RHT) ) has provided an update. Resonance Health Ltd, an Australian healthcare technology firm, provides non-invasive MRI-based Software-as-Medical Devices and imaging services that support clinicians and
Resonance Health Ltd ( ($AU:RHT) ) just unveiled an announcement. Resonance Health has signed a Strategic Alliance and Master Services Agreement with London-based Image Analysis Group, integrating its quantitative MRI
Resonance Health Limited is a global provider of healthcare technology and services, specializing in the design, development, and production of software-as-medical devices. The company serves markets across the Asia Pacific, Americas, Europe, Middle East, and Africa. Its portfolio of non-invasive, MRI-based diagnostic tools includes FerriScan, a system for quantifying liver iron concentration (LIC); FerriSmart, leveraging artificial intelligence (AI) for automated, real-time assessment of LIC; HepaFat-AI, an AI-driven solution for real-time, multi-metric liver fat quantification; CardiacT2, which provides dual analysis in conjunction with FerriScan to evaluate cardiac iron accumulation; HepaFat-Scan, a non-invasive MRI method for assessing liver fat within tissue; and LiverSmart, a comprehensive non-invasive MRI device integrating FerriSmart and HepaFat-AI for a unified report. The company further extends its offerings to include quantitative imaging measurements and Contract Research Organization (CRO) services, encompassing rigorous image analysis, imaging charter development, robust project and data management, proactive issue resolution, site tracking with clinical trial progress reports, and streamlined data flow coordination. They also provide comprehensive biomarker services, covering analysis of blood, urine, and protein analytes, alongside RNA, DNA, and genotyping. Their support for multinational and multicenter clinical trials extends to protocol development, subject inclusion/exclusion criteria assessment, dose modification strategies, new therapy safety profile evaluations, and establishing primary and secondary endpoints for drug efficacy. Additionally, they supply phantoms crucial for MRI machine calibration. Its client base includes clinicians, who utilize their solutions for managing human diseases, and pharmaceutical and therapeutic companies engaged in clinical research. Established in 1987, Resonance Health Limited maintains its headquarters in Burswood, Australia.
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 11 | 2 | 9 |
| Technical Analysis | 5 | 2 | 3 |
| Moving Averages | 6 | 0 | 6 |
